An Investigational Study to Assess the Effect of BMS-986177 on Aspirin in Healthy Participants


The purpose of this study is to investigate the effect of taking multiple doses of BMS-986177 when aspirin is taken once-daily. Eligible participants will receive twice-daily doses of BMS-986177 or placebo, with a once-daily dose of aspirin. The safety, tolerability and movement of BMS-986177 into, through and out of the body (pharmacokinetics/PK) will be assessed, as will the effect of BMS-986177 on the PK of aspirin.

Full Title of Study: “A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Coadministration of Multiple Doses of BMS-986177 on Aspirin in Healthy Participants”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Basic Science
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: November 16, 2017


  • Drug: Aspirin
    • 1 x 325 mg tablet of aspirin administered once daily
  • Drug: BMS-986177
    • 200 mg of BMS-986177 administered twice daily
  • Drug: Placebo
    • 200 mg of Placebo administered twice daily

Arms, Groups and Cohorts

  • Active Comparator: Aspirin
    • 325 mg tablet, once daily for 5 days (Day -5 to -1)
  • Experimental: BMS-986177 plus aspirin
    • 200 mg BMS-986177 twice daily and 325 mg tablet aspirin once daily (Day 1-7)
  • Placebo Comparator: Placebo plus aspirin
    • 200 mg Placebo twice daily and 325 mg tablet aspirin once daily (Day 1-7)

Clinical Trial Outcome Measures

Primary Measures

  • Number of participants with non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) leading to discontinuation when coadministered BMS-986177 (twice daily) and aspirin (once daily)
    • Time Frame: Up to 10 days
    • Safety and tolerability of multiple doses of BMS-986177 measured by investigator assessment
  • Number of potential clinically significant changes in electrical activity of the heart in participants coadministered BMS-986177 (twice daily) and aspirin (once daily)
    • Time Frame: Up to 10 days
    • Measured by electrocardiogram (ECG)
  • Number of participants with vital sign abnormalities.
    • Time Frame: Up to 10 days
  • Number of participants with physical examination abnormalities.
    • Time Frame: Up to 10 days
  • Number of participants with clinical laboratory abnormalities.
    • Time Frame: Up to 10 days

Participating in This Clinical Trial

Inclusion Criteria

  • Signed written consent form. – Healthy male and female participants (not of childbearing potential), determined by no clinically significant deviation from normal in medical history, physical examination, ECGs (electrocardiograms) and clinical laboratory determinations. – Women participants must have documented proof they are not of childbearing potential. – Males sexually active with women of childbearing potential must agree to follow instructions for method(s) of contraception for duration of treatment with BMS-986177, and for a total of 93 days after the last dose of BMS-986177; and must be willing to refrain from sperm donation during this time. Azoospermic males are exempt from contraceptive requirements. – Normal renal function at screening (Glomerula Filtration Rate ≥ 80 mL/min/1.73 m2. – Body Mass Index (BMI) of 18.0 kg/m2 to 32.0 kg/m2 inclusive. Exclusion Criteria:

  • Women who are of childbearing potential or breastfeeding. – Any significant acute or chronic illness. – History of gastroesophageal reflux disease, dyspepsia, protracted nausea or chronic diarrhea. – History of upper gastrointestinal ulcer disease within 6 months or current symptomatic or recent gastrointestinal disease that could impact absorption of study treatment. – Abnormal renal profile and/or hematuria (if male) within 3 months of study start. – History or evidence of abnormal bleeding and/or coagulation disorder and/or evidence of coagulopathy, prolonged or unexplained clinically significant bleeding, or frequent unexplained bruising or thrombus formation, or a history of spontaneous bleeding. – Any major surgery within 4 weeks of study treatment administration or planned within 2 weeks after completion of the study. – Donation of blood to a blood bank or in a clinical study (except screening or follow-up visit) within 4 weeks of study treatment administration (within 2 weeks for plasma only). – Blood transfusion within 3 months of study treatment administration. – Use of tobacco- or nicotine-containing products (including, but not limited to cigarettes, pipes, cigars, e-cigarettes, chewing tobacco, nicotine patches, nicotine lozenges or nicotine gum) within 6 months prior to study treatment administration. – History of allergy to aspirin or related compounds. Other protocol-defined inclusion/exclusion criteria could apply.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 55 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Bristol-Myers Squibb
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Bristol-Myers Squibb, Study Director, Bristol-Myers Squibb

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.